To the editor [2]

JAMA

Volumn 295, Issue 23, 2006, Pages 2720-2721

  Freeman, Michael R ^a   Solomon, Keith R ^b   Moyad, Mark ^c  

^a Urological Diseases Research Center   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; HUMAN; LETTER; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMATIC REVIEW;

EID: 33745273298     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.23.2720-b     Document Type: Letter

References (6)

1. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80.
2. Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology. 2005;66:1150-1154.
3. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959-968.
4. Sever PS, Poulter NR, Wedel H, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
5. Heart Protection Study Collaborative Group. MCR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals. Lancet. 2002;360:7-22.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.